Want to see AMLX full AI Analyst Report?
AMLX Stock Chart & Stats
$37.46
$0.82(4.66%)
At close: 4:00 PM EDT
$37.46
$0.82(4.66%)
Day’s Range― - ―
52-Week Range$10.83 - $41.14
Previous CloseN/A
Volume1.63M
Average Volume (3M)1.41M
Market Cap
$3.64B
Enterprise Value$1.75B
Total Cash (Recent Filing)$250.76M
Total Debt (Recent Filing)$5.25M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 05, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend Yield5.64%
Share Statistics
EPS (TTM)-1.41
Shares Outstanding125,513,050
10 Day Avg. Volume1,417,610
30 Day Avg. Volume1,414,573
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-87.31
Enterprise Value/Ebitda-11.69
Forecast
1Y Price Target
$46.63Price Target Upside24.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase III EfficacyThe positive pivotal result materially strengthens avexitide’s development profile and supports Amylyx’s planned NDA submission. If confirmed through regulatory review, clinically meaningful efficacy in an underserved condition could underpin a durable product franchise and improve future revenue prospects.
Strengthened Launch FundingThe capital raise provides substantial funding for regulatory execution, commercial preparation and manufacturing capacity without relying solely on current operating cash. This expands Amylyx’s ability to pursue avexitide milestones and sustain pipeline investment through a potential launch period.
Manufacturing ReadinessSecuring commercial-scale production ahead of a potential approval reduces a key execution hurdle for a clinical-stage company transitioning toward commercialization. Multiple suppliers and reserved capacity may support launch readiness and improve the operational foundation for future product supply.
Bears Say
Persistent Revenue Weakness And LossesAmylyx lacks a stable current revenue engine after RELYVRIO’s withdrawal, while large losses continue to consume resources. Until avexitide or another program generates commercial revenue, the company remains dependent on financing and successful execution to support ongoing operations.
Ongoing Cash BurnPersistent negative operating and free cash flow indicate that Amylyx cannot currently fund its activities from operations. Continued investment in trials, regulatory work and commercialization will therefore draw down cash or require additional financing if product revenue is delayed.
Regulatory And Label UncertaintyEven with encouraging trial results, the eventual FDA decision and label scope remain important uncertainties. A narrower indication could reduce the addressable market, require additional evidence for expansion, and limit the commercial opportunity relative to broader post-bariatric hypoglycemia treatment.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $10.83 and its highest was $41.14 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $3.64B.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.361 by -$0.029.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc pays a Quarterly dividend of $0.42 which represents an annual dividend yield of 5.64%. See more information on Amylyx Pharmaceuticals Inc dividends here
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.38.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 125,513,050 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.361. Following the earnings report the stock price went up 10.709%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amylyx Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.63 (24.47% Upside)
$46.63 (24.47% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 76%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 125.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.86%
12-Months-Change
Fundamentals
Return on Equity
-52.92%
Trailing 12-Months
Asset Growth
35.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
AMLX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear momentum: a pivotal Phase III (LUCIDITY) nearing top-line readout, active NDA and launch preparations, formal disease recognition via ICD-10 coding, a defined prevalent patient population (~160,000 U.S. patients with ~75% RYGB), and continued pipeline progress (AMX0035, AMX0114, AMX0318). Financially, the company has a solid cash balance with runway into 2028 but experienced a quarter-over-quarter cash decline (~10.4%), rising operating/SG&A costs (SG&A +40.4% YoY), and an unspecified one-time legal charge. Key risks remain: the outcome of the blinded Phase III readout and potential label limitations, early-stage EAP activation constraints, and possible additional manufacturing obligations. Overall the positives (imminent pivotal readout, launch preparedness, market opportunity, and pipeline advancement) outweigh the operational and financial headwinds discussed.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$46.63
▲(24.47% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
7.25% Insiders
21.71% Mutual Funds
0.04% Other Institutional Investors
57.98% Public Companies and
Individual Investors